Berkeley Scott Share Discussion Threads

[sirrah] 28/12/2001 21:32

lost patience with this one so was trade no 3 today
see you on another bb
think this will fall before it rises
see you at buy 27p

[kanga8] 28/12/2001 19:52

Transaction 23 today (28th) (400,000 @ 8p) must be a buy from someone in the know. something must be ready to happen no-one chucks £32k into the unknown. Before anybody says £32k is peanuts, no its not, not even to people with stacks of cash. They must have done thier homework on this one & therefore BGP must still be looking good. The only question is really is it going to be long or short term.
Seasons greetings to all.

[saturn5] 28/12/2001 16:35

Let us remember one thing

Banks are there to lend money and take the risk with it
The relevant banks would not have agreed to BGP paying SKP if they were not going to continue to finance BGP. They would have shut BGP down long ago,

[flyingbull] 28/12/2001 12:29

If one believes BGP is going bankrupt, there is no point in buying at any price
fb.

[cockney rebel] 28/12/2001 10:17

SOZ, Dup Post

Simple - WIN or LOSE

On a fruit machine you shuve in a coin, pull the handle, watch three reels go round, then say, ah nearly and walk away - Pure Luck

With BGP you wait until the end of January, walk around the fruit machine, put your hand on your chin and say "ah RBOS has given this machine a service, I think I'll shuve this coin in the machine now" after all, the machine is still here, nobodys taken it away therefore people (Business Men) must be interested in its presence/future" - Pure Luck - not at this stage - educated gamble!

Buy a couple of hundred to start, then some more, min the risk, when the Co's on a bull say 30% from initial investment, go for it! and remember, the stool to the left of the bar at the St Tropez Hotel is Mine!

Just hold til Jan 30th 2002

[cockney rebel] 28/12/2001 10:04

Simple - WIN or LOSE

On a fruit machine you shuve in a coin, pull the handle, watch three reels go round, then say, ah nearly and walk away - Pure Luck

With BGP you wait until the end of January, walk around the fruit machine, put your hand on your chin and say "ah RBOS has given this machine a service, I think I'll shuve this coin in the machine now" after all, the machine is still here, nobodys taken it away therefore people (Business Men) must be interested in its presence/future" - Pure Luck - not at this stage - educated gamble!

Buy a couple of hundred to start, then some more, min the risk, when the Co's on a bull say 30% from initial investment, go for it! and remember, the stool to the left of the bar at the St Tropez Hotel is Mine!

Just hold til Jan 30th 2002

[lovegod] 28/12/2001 09:51

guess its all or nothing on this one now

[cockney rebel] 28/12/2001 08:48

The company stops trading because it has no liquid funds to pay Wages, Electricity, Gas, Materials to buy for future trading etc etc, but this CO does have some cash and assets, ie property to sell off

As mentioned, shrewd people are simply waiting until late January 2002 to see if that is the case and then buy at the so-called 30% rule, this may not drop to 2p but Im not buying until its on a bull

Ive watched this Co fall from 200p and still waiting

[dryboy] 28/12/2001 00:34

anyone any ideas whether that 800000 was a buy or sell

[lovegod] 28/12/2001 00:12

didn't know it had any left to sell.

[aggressive saver] 27/12/2001 23:58

I cant afford to lose money in risky stocks so I will give this one a miss.

[bensoni] 27/12/2001 19:22

Anyone know what the 859,741 trade at 8.5p was this morning? It's down as a ? on the trades page.

[lovegod] 27/12/2001 19:20

i think last week in january is going to be the interesting one. until then can we expect further increases or is the bid gonna stay at 7.5 ?

[mad trader] 27/12/2001 17:11

at 2p not before

[cockney rebel] 27/12/2001 14:30

Reminder re: Selling the Family Silver

Bioglan said that, though the North American Solaraze contract had been expected to generate substantial long term revenues, the deal with Quintiles is in the best interests of the company "in view of the current situation".

Wait until the RBOS deadline, then buy in the January sales

[cockney rebel] 27/12/2001 14:16

Ha, attitude problem and Loser, get real TURKEY, if you wanna 'slag' me, at least be more convincing

Reminder re: Selling the Family Silver

Bioglan said that, though the North American Solaraze contract had been expected to generate substantial long term revenues, the deal with Quintiles is in the best interests of the company "in view of the current situation".

Research - Im still laughing

[linesal1] 27/12/2001 14:09

I have read all that you have pasted here but still i can not believe that they are all the facts,several papers i know have reported in this way but i do not believe that one drug can send bgp down, it is a culmination of pyramid deals and trying to be over ambitious with the future that as brought all this on,
my feeling is that the core of the company is ok it is just the way it has been run and if they can restructure they will be ok the products are there they just need to work at it. and they will (i hope)only the future will tell.
p.s did you get an attitude problem for christmas "loser"

[mad trader] 27/12/2001 14:08

who cares its only pin money no real players here just sheep hoping for 10% well they aint going to get it.

[cockney rebel] 27/12/2001 13:52

Maybe it wasnt possible for you to read this either ...

LONDON (AFX) - Bioglan Pharma PLC remains a 'sell', according to WestLB Panmure's Emma Palmer, who believes that liquidation has to be a strong possibility for the company.

Bioglan's straitened situation, said Palmer, has forced it to relinquish US
rights to one of its potentially most valuable products, Solaraze (licensed from
SkyePharma to a third party)


Research LINESAL1 - plz Im laughing too much already

[cockney rebel] 27/12/2001 13:43

LINESAL1, as always you 'shout off' without thought, wanna impress your buddies, try the MONI thread

READ the press, this company has been held up simply because RBOS want a satisfactory conclusion to its debt repayment
the future of the company has been many times stated as virtual bankrupt, selling the rights has sealed that

READ BELOW if you are capable ...


LONDON (AFX) - Bioglan Pharma PLC transferred its rights to market and sell
SkyePharma PLC's new Solaraze skin treatment in North America to Quintiles
Transnational Corp for 15 mln stg.
The announcement means a last-minute reprieve from bankruptcy for Bioglan,
though it warned that if there is no satisfactory outcome to current talks with
potential bidders or financial backers, it won't have enough working capital to
see out the next 12 months.
It said that, if the Quintiles deal had not been agreed immediately, "the
company would have been unable to meet its financial commitments as they fell
due and consequently would have been unable to continue to trade, resulting in
the appointment of receivers/liquidators/ administrators," it said.
Bioglan said it is talks with potential bidders for the company and with
other potential financiers about a recapitalisation of the company. But it added
that, without any new agreement bringing funds in, it does not have enough
working capital for the next 12 months, though the Quintiles deal means it will
be able to make it through to the end of its financial year in January.
It said it is unlikely that any offer for Bioglan would exceed its current
level of debt.
The deal with Quintiles comes after SkyePharma took steps to tear up its
agreement with Bioglan after Bioglan had got into financial difficulties.
Bioglan had been negotiating the multi-million dollar acquisition of a range
of dermatology products in the US and had invested heavily in a new sales and
marketing organisation there.
But, after disagreements over fundraising and board resignations, the deal
collapsed, leaving Bioglan financially stretched.
Solaraze is a skin cream for treating a skin complaint that often develops
into skin cancer. The product has already been launched in Europe, under a
continuing licensing agreement with Bioglan.
Bioglan said that, following the agreement on the North American rights to
Solaraze, its banks have agreed to extend its debt standstill arrangements until
the end of January. The previous agreement was due to run out today.
Bioglan said the money it is getting from Quintiles will enable it to meet
its projected borrowing requirements in December and January.
"Although there can be no assurances that the existing financing will be
extended beyond Jan 31, Bioglan remains in active discussion with its banks and
certain third parties with a view to achiev a longer-term solution for the
company, " it said.
Bioglan has also agreed to increase payments to SkyePharma under the
continuing Solaraze contract.
Bioglan had been due to pay SkyePharma 10 mln usd by the end of this month.
It said it will increase that to 12.5 mln usd due immediately, which will be
paid out of the Quintiles proceeds.
As part of the deal, SkyePharma has agreed that Bioglan is no longer in
breach of its obligations under the Solaraze Contract, as it had previously
claimed.
Bioglan said that, though the North American Solaraze contract had been
expected to generate substantial long term revenues, the deal with Quintiles is
in the best interests of the company "in view of the current situation".
Bioglan said it expects to be contracted to undertake certain services for
Quintiles in relation to Solaraze, including marketing, distribution, promotion
and manufacturing, for which Bioglan will receive a revenue stream.
A third party manufacturer carries out manufacturing for Solaraze in the US
under contract.
SkyePharma's chief executive Michael Ashton said that the Quintiles deal
"should remove much of the uncertainty surrounding the commercial future of
Solaraze, which is now essentially isolated from the outcome of Bioglan's
negotiations with its banks and potential partners."
He said SkyePharma is pleased that Quintiles has been recruited as a
partner.
"This is a substantial company with proven sales and marketing experience.
We are confident that, with their backing and experience, we have a strong
partnership ready to promote Solaraze when it is launched in the US in January."

[linesal1] 27/12/2001 13:27

IM missing somthing here since when did bgp sell the marketing rights to skp,
please do a little more research and come back with facts(skp own the drug).
only the rights to market in america have been sold to Quintilles and bgp will still receive a revenue stream from this and be apart of the manufacturing of it.
and if you think one drug keeps a company the size of bgp afloat your wrong they have a good portfolio of drugs solereaze being the most marketable and they still have the rights for it in europe where it is doing well,it is pointless me listing all the drugs and services they provide but if you delve a little deeper you will see for yourself.

[cockney rebel] 27/12/2001 11:52

The company has just sold the family silver to SKP

Run !

[lovegod] 27/12/2001 11:45

gota feeling you might be right Harry. Seems like lots of small buys.